What are the current guidelines for the management of dyslipidaemia in adults?

Current Dyslipidaemia Management Guidelines

The cornerstone of dyslipidaemia management is risk stratification using the SCORE system, followed by aggressive LDL-cholesterol lowering with statins to specific targets based on cardiovascular risk category, with very high-risk patients requiring LDL-C <1.8 mmol/L (70 mg/dL) or ≥50% reduction. 1

Risk Stratification Framework

The 2016 ESC/EAS guidelines establish four distinct cardiovascular risk categories that determine treatment intensity 1:

Very High Risk (LDL-C target <1.8 mmol/L or 70 mg/dL)

• Documented CVD by invasive/non-invasive testing (coronary angiography, nuclear imaging, stress echo, carotid plaque) 1
• Previous myocardial infarction, acute coronary syndrome, or any coronary/arterial revascularization 1
• Ischaemic stroke or peripheral arterial disease 1
• Type 2 diabetes or Type 1 diabetes with target organ damage (microalbuminuria) 1
• Moderate to severe chronic kidney disease (GFR <60 mL/min/1.73 m²) 1
• Calculated 10-year SCORE risk ≥10% 1

High Risk (LDL-C target <2.6 mmol/L or 100 mg/dL)

• Markedly elevated single risk factors including familial hypercholesterolaemia or severe hypertension 1
• Calculated SCORE ≥5% and <10% for 10-year fatal CVD risk 1

Moderate Risk (LDL-C target <3.0 mmol/L or 115 mg/dL)

• SCORE ≥1% and <5% at 10 years 1
• Risk further modified by family history of premature CAD, abdominal obesity, physical inactivity, HDL-C, triglycerides, and inflammatory markers 1

Low Risk (SCORE <1%)

• Lifestyle advice to maintain low-risk status 1

Screening Recommendations

Total cardiovascular risk estimation using SCORE is recommended for all asymptomatic adults >40 years without established CVD, diabetes, CKD, or familial hypercholesterolaemia. 1

Specific screening indications include 1:

• Adult men ≥40 years and women ≥50 years or post-menopausal 1
• All patients with documented atherosclerosis in any vascular bed, regardless of age 1
• Individuals with family history of premature CVD 1
• Patients with central obesity (waist ≥94 cm men, ≥80 cm women) or BMI ≥25 kg/m² 1
• Autoimmune inflammatory conditions (rheumatoid arthritis, SLE, psoriasis) 1

Laboratory Assessment

LDL-cholesterol should be used as the primary lipid parameter for screening, risk estimation, diagnosis, and management. 1

• HDL-C is an independent risk factor and included in HeartScore electronic version 1
• Non-HDL cholesterol and apolipoprotein B are secondary targets in high/very high-risk patients with combined dyslipidaemia 2

Treatment Algorithm

Primary Treatment Target: LDL-Cholesterol 1

For Very High Risk patients:

• Target LDL-C <1.8 mmol/L (70 mg/dL) 1
• OR achieve ≥50% reduction if baseline LDL-C is 1.8-3.5 mmol/L (70-135 mg/dL) 1

For High Risk patients:

• Target LDL-C <2.6 mmol/L (100 mg/dL) 1
• OR achieve ≥50% reduction if baseline LDL-C is 2.6-5.1 mmol/L (100-200 mg/dL) 1

Statin Therapy

A statin is the first-line treatment and should be titrated to the highest recommended or highest tolerable dose to reach LDL-C goals. 1

• High-dose statins should be initiated early after acute coronary syndrome admission 1
• In post-MI patients, statin therapy is indicated irrespective of baseline LDL-C levels 1
• Statins are recommended for older adults with established CVD using the same approach as younger patients 1

Diabetic Patients

Statin therapy should be added to lifestyle modifications regardless of baseline lipid levels in all diabetic patients >40 years with ≥1 cardiovascular risk factor. 1, 3

• Goal LDL <100 mg/dL without vascular disease 1, 3
• Goal LDL <70 mg/dL with established vascular disease and diabetes 1, 3
• HDL targets: >40 mg/dL for men, >50 mg/dL for women 3

Non-Statin Therapy

When statins are inadequate or not tolerated 3:

• Ezetimibe (cholesterol absorption inhibitor) 3
• Bile acid binding resins 3
• PCSK9 inhibitors show no effect modification by presence of CKD in outcome trials 4
• Bempedoic acid and inclisiran are emerging options, though outcome data in specific populations remain limited 4

Triglyceride Management in Diabetes 3

For triglycerides 150-199 mg/dL: Intensify lifestyle modifications and optimize glycemic control first 3

For triglycerides 200-399 mg/dL: Consider fibric acid derivative (gemfibrozil or fenofibrate) or niacin 3

For triglycerides ≥400 mg/dL: Immediate pharmacological treatment required to prevent pancreatitis, with fibrate as primary agent 3

Familial Hypercholesterolaemia Detection

Suspect familial hypercholesterolaemia in patients with:

• CHD before age 55 years (men) or 60 years (women) 1
• Relatives with premature fatal/non-fatal CVD 1
• Relatives with tendon xanthomas 1
• Severely elevated LDL-C: adults >5 mmol/L (190 mg/dL), children >4 mmol/L (150 mg/dL) 1

Critical Pitfalls to Avoid

Do not delay statin therapy in diabetic patients ≥40 years with cardiovascular risk factors—initiate regardless of baseline LDL levels. 3

• Do not treat triglycerides before optimizing glycemic control, as improved glucose control effectively reduces triglycerides 3
• Avoid combining gemfibrozil with statins due to increased myositis risk; use fenofibrate if combination therapy needed 3
• Exercise clinical judgment in older adults rather than automatically prescribing based solely on age-driven SCORE values 1
• Monitor for rhabdomyolysis with statin-fibrate combinations, especially with renal insufficiency 3
• Use niacin cautiously in diabetics as it can significantly worsen hyperglycemia 3

Monitoring Protocol

• Measure lipids annually in all adult diabetic patients 3
• Reassess 6 weeks after initiating lifestyle modifications 3
• Evaluate pharmacotherapy response at 4-8 week intervals 3